Finally, it should be remembered that all of this translates into
a considerable burden for our patients. Evidence-based medicine
will lead to the prescription of 4 or more drugs, usually
indefinitely. We must be prepared to make a case for the patient to
accept that it really is worthwhile. At the moment, for whatever
reasons, most of these proven measures are underused.
RReeffeerreenncceess
1 Heart Outcomes Prevention Evaluation Study Investigators. Effects of
ramipril on cardiovascular and microvascular outcomes in people with
diabetes mellitus: results of the HOPE study and MICRO-HOPE
substudy. Lancet2000; 335555 : 253–9.
FFuurrtthheerr rreeaaddiinngg
Frishman WH, Cheng A. Secondary prevention of myocardial infarction:
role of beta-adrenergic blockers and angiotensin converting enzyme
inhibitors. Am Heart J 1999; 113377 : S25–34
Kendall MJ, Horton RC, eds. Preventing coronary artery disease.
Cardioprotective therapeutics in practice. London: Martin Dunitz, 1998.
Michaels AD. The secondary prevention of myocardial infarction. Current
Probl Cardiol 1999; 1100 : 617–77
Velasco JA. After 4S, CARE and LIPID is evidence-based medicine being
practised? Atherosclerosis1999; 114477 ((ssuuppppll 11 )): S39–44